Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06674941 · ClinicalTrials.gov registry record · Phase 1
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT06674941 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 44 participants.
The verdict
NCT06674941, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an injection device in non-Japanese participants.
Interventions
- DRUG Teprotumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06674941
The ClinicalTrials.gov registry entry for NCT06674941 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Teprotumumab is the first listed.
NCT06674941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06674941 about?
NCT06674941 is a clinical study titled "A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants". The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an i...
What is the current status of trial NCT06674941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-03-24. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT06674941?
The interventions under investigation include: Teprotumumab (DRUG).
Who is sponsoring clinical trial NCT06674941?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.